|
| 1 |
|
Conditions listed in this trial |
|
|
Leukemia |
|
|
Chronic Myeloid Leukemia |
|
|
Myelodysplastic Syndrome |
|
|
Diffuse Large Cell Lymphoma |
|
|
Hodgkin Lymphoma |
|
|
Chronic Lymphocytic Leukemia |
|
|
Multiple Myeloma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Hodgkin Disease |
|
|
Leukemia, B-Cell |
|
|
Leukemia, Lymphocytic, Chronic, B-Cell |
|
|
Leukemia, Lymphoid |
|
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
|
|
Leukemia, Myeloid |
|
|
Lymphoma |
|
|
Lymphoma, Large B-Cell, Diffuse |
|
|
Myelodysplastic Syndromes |
|
|
Neoplasms, Plasma Cell |
|
|
Preleukemia |
|
|
Syndrome |
|
| 3 |
|
More general conditions related to this trial |
|
|
Blood Protein Disorders |
|
|
Bone Marrow Diseases |
|
|
Cardiovascular Diseases |
|
|
Disease |
|
|
Hematologic Diseases |
|
|
Hemorrhagic Disorders |
|
|
Hemostatic Disorders |
|
|
Immune System Diseases |
|
|
Immunoproliferative Disorders |
|
|
Lymphatic Diseases |
|
|
Lymphoma, B-Cell |
|
|
Lymphoma, Non-Hodgkin |
|
|
Lymphoproliferative Disorders |
|
|
Myeloproliferative Disorders |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Paraproteinemias |
|
|
Pathologic Processes |
|
|
Precancerous Conditions |
|
|
Vascular Diseases |
|
| 4 |
|
Interventions listed in this trial |
|
|
Treosulfan IV |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Treosulfan |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Alkylating Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Pharmacologic Actions |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
IRCCS San Raffaele |
